Header Logo

Connection

Christopher Goetz to Dyskinesia, Drug-Induced

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Dyskinesia, Drug-Induced.
Christopher Goetz
Connection Strength
3.917
Dyskinesia, Drug-Induced
  1. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.572
  2. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.423
  3. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.384
  4. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.354
  5. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.317
  6. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.309
  7. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.288
  8. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.211
  9. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.191
  10. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999; 14 Suppl 1:48-53.
    View in: PubMed
    Score: 0.159
  11. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.133
  12. Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol. 1988; 49:185-97.
    View in: PubMed
    Score: 0.074
  13. The pathophysiology of tardive dyskinesia. J Clin Psychiatry. 1985 Apr; 46(4 Pt 2):38-41.
    View in: PubMed
    Score: 0.061
  14. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.057
  15. Animal models of tardive dyskinesia: their use in the search for new treatment methods. Mod Probl Pharmacopsychiatry. 1983; 21:5-20.
    View in: PubMed
    Score: 0.052
  16. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
    View in: PubMed
    Score: 0.052
  17. Drug-induced extrapyramidal disorders - a neuropsychiatric interface. J Clin Psychopharmacol. 1981 Sep; 1(5):297-303.
    View in: PubMed
    Score: 0.048
  18. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
    View in: PubMed
    Score: 0.046
  19. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
    View in: PubMed
    Score: 0.044
  20. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov Disord. 1998 May; 13(3):477-80.
    View in: PubMed
    Score: 0.038
  21. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.020
  22. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May; 35(5):749-51.
    View in: PubMed
    Score: 0.015
  23. Speech abnormalities in tardive dyskinesia. Arch Neurol. 1984 Mar; 41(3):273-6.
    View in: PubMed
    Score: 0.014
  24. Animal models of tardive dyskinesias. Clin Neuropharmacol. 1983 Jun; 6(2):129-35.
    View in: PubMed
    Score: 0.013
  25. Anticholinergics and tardive dyskinesia. Am J Psychiatry. 1980 Nov; 137(11):1470-1.
    View in: PubMed
    Score: 0.011
  26. Tardive dyskinesia: review and update. Am J Psychiatry. 1980 Aug; 137(8):900-8.
    View in: PubMed
    Score: 0.011
  27. Recent advances in the biochemical pharmacology of extrapyramidal movement disorders. Adv Exp Med Biol. 1977; 90:21-47.
    View in: PubMed
    Score: 0.009
  28. The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig. Life Sci. 1981 May 11; 28(19):2173-8.
    View in: PubMed
    Score: 0.003
  29. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology. 1981 Apr; 31(4):473-6.
    View in: PubMed
    Score: 0.003
  30. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med. 1978 Mar; 88(3):327-31.
    View in: PubMed
    Score: 0.002
  31. Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc. 1977; 102:80-3.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.